About SignalLens
SignalLens identifies publicly listed companies positioned to benefit from frontier technology transitions using a systematic research framework. Coverage spans four sectors: Compute and Intelligence, Energy, Materials, and Climate Tech, Sovereign and Industrial, and Life Tech.
The thesis behind the publication is what we call the Sub-Surface Trade: the equity opportunity that exists in the gap between when a frontier technology’s commercialisation evidence becomes readable and when the market prices it. Most market commentary works at the surface — the press release, the chart, the quarterly headline — by which time the equity has already moved. SignalLens reads the layers below: patent prosecution accelerating, government grants entering Phase II, specialist VC follow-ons, binding offtake agreements buried in regulatory filings. The Sub-Surface Trade is the discipline of identifying production-scale transitions while they are still strata.
How the analysis works
Every published thesis runs through four interlocking analytical pillars:
The Signal Stack — a six-layer evidence assessment scoring whether a technology has genuine commercialisation momentum, or is trapped in a hype cycle.
The Commercialisation Cascade — a five-stage timing framework, from Discovery through Scale. SignalLens focuses on the Stage 3 → Stage 4 transition, where the steepest equity re-ratings typically occur.
The Beneficiary Map — a four-tier classification (pure plays, optionality bets, supply chain and enablers, second-order beneficiaries) that converts a technology thesis into specific listed equities on global exchanges.
Kill and Acceleration Criteria and the Catalyst Calendar — every thesis carries the quantified evidence that would invalidate it, alongside a dated calendar of upcoming events that move equities.
The full methodology is laid out in the pinned article: The Sub-Surface Trade — Frontier Technology, Mapped to Public Equities.Start there.
What you receive
Three content formats, each doing one job:
Anchor – A deep-dive thesis on a single technology: the full Signal Stack assessment, Cascade staging, Beneficiary Map, Kill and Acceleration Criteria, and Catalyst Calendar. The reason to subscribe. Monthly.
Pulse — a weekly signal scan across all four sectors. Brisk, brief, forward-looking. Free.
Lens Flare — a rapid catalyst alert when a tracked thesis sees a material development. Capped at two per month. Free.
For now, every Anchor is free. When paid subscriptions are introduced, the free preview will carry the thesis — the technology, the framework, the staging. The paid section will name the companies, tier classifications, kill criteria and catalyst calendars that are the working output of the research. Pulse and Lens Flare stay free, always.
What SignalLens will not do
No buy, sell, or hold recommendations. No price targets. No tokens, IPO allocations, or sponsored content. No chasing whatever technology trended on social media last week. SignalLens is not investment advice. It is a research framework, applied transparently, to help readers see what is happening in technology before it is priced.
About the Author
SignalLens is built on a working belief: deep-tech writers rarely understand public equities, and equity writers rarely understand frontier technology. Reading across both is the qualification this publication requires.
The publication is written by Robert Kerr. The work and analytical frameworks draw on a Manufacturing and Materials Engineering background (First Class Honours), a long career in IT Systems and Development, Operations Management across Energy Storage R&D, business valuation and commercial structuring across multiple industries, and four years inside the financial advice industry.
This is not investment advice. SignalLens does not provide buy, sell, or hold recommendations and does not set target prices. All investment decisions should be made in consultation with a qualified financial adviser. The author may hold positions in companies discussed. Past analysis does not guarantee future accuracy.
